Is Trident Texofab overvalued or undervalued?

As of 29 August 2025, Trident Texofab's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company is still considered overvalued. Key ratios reveal a PE Ratio of 133.86, an EV to EBITDA of 76.80, and a PEG Ratio of 6.36, all of which are significantly higher than typical industry benchmarks.
In comparison to its peers, Trident Texofab's valuation metrics stand out unfavorably; for instance, PTC India, which is rated very attractive, has a PE Ratio of just 8.35 and an EV to EBITDA of 4.44. Other peers like Lloyds Enterprises and Elitecon International are also categorized as very expensive with PE Ratios of 38.87 and 752.77, respectively. Despite Trident Texofab's stock outperforming the Sensex with a remarkable 456.44% return over the past year, its current valuation suggests it remains overvalued in the market.